Edition:
India

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

77.67EUR
6:42pm IST
Change (% chg)

€-1.61 (-2.03%)
Prev Close
€79.28
Open
€79.75
Day's High
€79.84
Day's Low
€77.40
Volume
232,815
Avg. Vol
442,656
52-wk High
€89.75
52-wk Low
€53.84

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

Beta: 1.05
Market Cap(Mil.): €4,412.26
Shares Outstanding(Mil.): 50.87
Dividend: --
Yield (%): --

Financials

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

27 Oct 2017

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

27 Sep 2017

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

10 Aug 2017

BRIEF-Galapagos H1 revenues up at EUR 73.0 mln

* ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO

28 Jul 2017

BRIEF-Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos

* SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S.

28 Jul 2017

BRIEF-Galapagos announces new phase 2 study with filgotinib

* NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​

05 Jul 2017

BRIEF-Galapagos announces successful completion of Phase 1

* GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES

20 Jun 2017

Earnings vs. Estimates